Healthcare in a post-COVID world: What have we learnt?

11 April 2022

*Sponsored Content

An Expert View from Gaëtan Leblay, Managing Director, Janssen UK & Ireland.

It has been over two years since the COVID-19 pandemic was declared and our ’normal’ altered beyond recognition. The pandemic and subsequent lockdowns have shone a light on the inequality that exists, particularly in the healthcare sector. We have also been witness to the impact social restrictions have had on physical and mental health, and the need for tools to manage these adjustments in daily life. This shift has emphasized the growing need for a hybrid world, bridging the divide between digital and face-to-face interaction. As we look to living in the now, what have we learnt from this period and what can we bring to our new future?

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK